WVE-004, Wave Life Sciences‘ experimental therapy for people with amyotrophic lateral sclerosis (ALS) associated with mutations in the C9ORF72 gene, has demonstrated proof-of-concept efficacy in cell and animal models, a new study shows. The nucleic acid-based therapy was able to “potently” reduce the toxic RNA molecules and small proteins…

Merit E. Cudkowicz, MD,  is the winner of the inaugural Target ALS Rebecca Luker Courage Award in recognition of her work and efforts to help  amyotrophic lateral sclerosis (ALS) patients and the ALS community. Cudkowicz is the chief of neurology at Massachusetts General Hospital, a professor…

More than 5,000 people are diagnosed with amyotrophic lateral sclerosis (ALS) each year, and the out-of-pocket costs of care are an estimated $250,000 for each person with the disease, according to the ALS Association. These are just a couple of the statistics about ALS that advocates, organizations, and…

Treatment with Coya Therapeutics‘ ALS001, a regulatory T-cell (Treg) therapy being developed for amyotrophic lateral sclerosis (ALS), was found to reduce markers of oxidative stress — a type of cell damage — and inflammation in a small early trial. The experimental Treg therapy was tested in a Phase 1…

An international team of researchers is asking adults with amyotrophic lateral sclerosis (ALS) and their family caregivers to complete an online survey about their experiences with stigma around the disease. The results are expected to help researchers better understand negative attitudes and untrue beliefs about ALS faced by patients…

Researchers at the University of Michigan are focused on establishing cause and effect relationships between environmental and occupational exposures with amyotrophic lateral sclerosis (ALS). They hope this information will shed light on the mechanisms behind the disease and identify modifiable risk factors, which may have implications in preventing ALS.

“Clustering” people with amyotrophic lateral sclerosis (ALS) based on biological data could be useful for identifying those most likely to have slower or faster progressing disease, a new study shows. The findings were presented in a talk, “Fast Progression in Amyotrophic Lateral Sclerosis: Pathways and Biomarkers…

Note: Frontiers in Genetics, the publisher of the study discussed in this ALS News Today news story, received a request from the article’s authors to retract it in light of new information indicating that the variants reported in the study might not be meaningful; instead, they may actually result from…

The ALS Association is calling for applications for a new Seed Grant Program designed to support exploratory amyotrophic lateral sclerosis (ALS) research. The one-year grants of up to $50,000 each will fund investigations that could have a significant impact on the progressive neurodegenerative disorder. Specifically, funded projects…

Shortly after Jeremy Schreiber, then 39, was diagnosed with amyotrophic lateral sclerosis (ALS), he had another life-altering decision to make. “I had a choice — climb into bed and pull the covers over my head or say ‘[expletive] it’ and fight this thing head-on,” Schreiber wrote in an excerpt…